.jpg "Neos Therapeutics (NASDAQ: NEOS)")
In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Neos Therapeutics (NASDAQ: NEOS), with a price target of $20. The company’s shares opened today at $7.95.
Chen said:
“Positives from the quarter that support our thesis 1) On 01/10/18 NEOS announced that study findings for two of its ADHD medications, ER, were presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on 02/20/18 PDL Biopharma (Not Covered) announced termination of interest in acquiring 02/26/18 NEOS announced the U.S. launch of Adzenys ER, making it NEOS’s third ADHD product launch in less than two years; 4) as discussed at the company’s analyst day in March of 2018, NEOS plans to advance its drug candidate for the treatment of nausea and vomiting into the clinic in 2H18 and to identify one additional branded product candidate in CNS or gastroenterology in 2018; and 5) as of 03/31/18 the company held $37.2MM in cash and cash equivalents.”
According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Neos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $17.
See today’s analyst top recommended stocks >>
Based on Neos Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.23 million. In comparison, last year the company had a GAAP net loss of $17.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX.
